ArticleThe Journal of clinical investigation1994
Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines.
Article in The Journal of clinical investigation, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 352 citations in OpenAlex.
- Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors.Brain pathology (Zurich, Switzerland) · 1997Trial
- HIV-Induced Apoptosis: Host Defense and Viral Strategy.Biology · 2025Review
- Knowledge structure and hotspots research of glioma immunotherapy: a bibliometric analysis.Frontiers in oncology · 2023Article
- CRISPR/Cas9-mediated abrogation of CD95L/CD95 signaling-induced glioma cell growth and immunosuppression increases survival in murine glioma models.Journal of neuro-oncology · 2022Article
- CD95 gene deletion may reduce clonogenic growth and invasiveness of human glioblastoma cells in a CD95 ligand-independent manner.Cell death discovery · 2022Article
- Cancer Stem Cells and Targeting Strategies.Cells · 2019Review
- Cell growth inhibition and apoptotic effects of a specific anti-RTFscFv antibody on prostate cancer, but not glioblastoma, cells.F1000Research · 2017Article
- Harnessing the apoptotic programs in cancer stem-like cells.EMBO reports · 2015Review
- Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway.Journal of translational medicine · 2011Article
- APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.Neuro-oncology · 2011Article
- Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.Clinical Medicine Insights. Oncology · 2011Article
- FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors.Molecular cancer · 2010Article
- Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.Molecular cancer · 2010Review
- APO-1/Fas gene: Structural and functional characteristics in systemic lupus erythematosus and other autoimmune diseases.Indian journal of human genetics · 2009Article
- Roles of proinflammatory cytokines and the Fas/Fas ligand interaction in the pathogenesis of inflammatory myopathies.Immunology · 2009Article
- Topotecan enhances immune clearance of gliomas.Cancer immunology, immunotherapy : CII · 2009Article
- Mitomycin C induces multidrug resistance in glaucoma surgery.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2008Article
- Intracellular application of TNF-alpha impairs cell to cell communication via gap junctions in glioma cells.Journal of neuro-oncology · 2008Article
- Current immunotherapeutic strategies for central nervous system tumors.Surgical oncology clinics of North America · 2007Review
- Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent.The Journal of clinical investigation · 2007Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fas/APO-1 is a transmembrane protein of the nerve growth factor/TNF alpha receptor family which signals apoptotic cell death in susceptible target cells. We have investigated the susceptibility of seven human malignant glioma cell lines to Fas/APO-1-dependent apoptosis. Sensitivity to Fas/APO-1 antibody-mediated cell killing correlated with cell surface expression of Fas/APO-1. Expression of Fas/APO-1 as well as Fas/APO-1-dependent cytotoxicity were augmented by preexposure of human malignant glioma cells to IFN gamma and TNF alpha. Further, pretreatment with TGF beta 2, IL1 and IL8 enhanced Fas/APO-1 antibody-induced glioma cell apoptosis whereas other cytokines including TNF beta, IL6, macrophage colony-stimulating factor, IL10 and IL13 had no such effect. None of the human malignant glioma cell lines was susceptible to TNF alpha-induced cytotoxicity. Fas/APO-1 antibody-sensitive glioma cell lines (n = 5), but not Fas/APO-1 antibody-resistant glioma cell lines (n = 2), became sensitive to TNF alpha when co-treated with inhibitors of RNA and protein synthesis. Resistance of human glioma cells to Fas/APO-1 antibody-mediated apoptosis was mainly related to low level expression of Fas/APO-1 and appeared not to be linked to overexpression of the anti-apoptotic protooncogene, bcl-2. Given the resistance of human malignant glioma to surgery, irradiation, chemotherapy and immunotherapy, we propose that Fas/APO-1 may be a promising target for a novel locoregionary approach to human malignant glioma. This strategy gains support from the demonstration of Fas/APO-1 expression in ex vivo human malignant glioma specimens and from the absence of Fas/APO-1 in normal human brain parenchyma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.